Nivolumab (Opdivo®) for NSCLC

Assessment Status Assessment Process Complete
Drug Nivolumab
Brand Opdivo®
Indication Opdivo® is indicated for the treatment of locally advanced or metastatic squamous NSCLC after prior chemotherapy in adults.
Assessment Process
Rapid review commissioned 02/07/2015
Rapid review completed 16/07/2015
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 30/10/2015
NCPE assessment completed 10/03/2016

Technical Summary

The HSE has approved reimbursement following confidential price negotiations September 2018